Novo Nordisk (NOVOB DC) does not expect to see a biosimilar of semaglutide in China this year, it is protected until April 2027 in China
Context
Novo Nordisk's announcement regarding the protection of semaglutide until 2027 in China reassures investors about its market position and competitive advantage in a lucrative sector. The absence of a biosimilar this year suggests sustained revenue potential without immediate competitive pressures, which could positively impact the company's stock performance as the market factors in delayed competition.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US EQUITIES